lympholyte-m density gradient centrifugation (Dakewe Biotech Co)
90
Structured Review
Dakewe Biotech Co
lympholyte-m density gradient centrifugation
Lympholyte M Density Gradient Centrifugation, supplied by Dakewe Biotech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lympholyte-m+density+gradient+centrifugation/lympholyte+m+density+gradient+centrifugation/pm29779765-52-6-10
Average 90 stars, based on 1 article reviews
Lympholyte M Density Gradient Centrifugation, supplied by Dakewe Biotech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lympholyte-m+density+gradient+centrifugation/lympholyte+m+density+gradient+centrifugation/pm29779765-52-6-10
Average 90 stars, based on 1 article reviews
lympholyte-m density gradient centrifugation - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells. Article Snippet: It is believed that central memory T cells (TCM) provide long-term protection against tuberculosis (TB).. However, the effects of TB subunit vaccine immunization schedule, especially the vaccination intervals, on T cell immune memory is still unclear.. In this study, mice were immunized with fusion protein ESAT6-Ag85B-MPT64 (190–198)-Mtb8.4-Rv2626c (LT70) based subunit vaccine three times according to the following schedules: 1 0, 3rd and 6th week respectively (0-3-6w), 2 0, 4th and 12th week (0-4-12w), and 3 0, 4th and 24th week (0-424w). Article Title: Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Article Snippet: To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4–HspX (MH for short) without affinity tag with potential advantage for clinical use.. The human T-cell responses to MH were evaluated for its immunogenicity.. Furthermore, MH was emulsified in an adjuvant composed of N,N′-dimethyl-N,N′dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. Article Title: Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Article Snippet: The current vaccine against Mycobacterium tuberculosis, Mycobacterium bovis bacillus Calmette-Guérin (BCG), has been used as the only vaccine against tuberculosis (TB) for about 90 years.. It has proven capacity to efficiently prevent severe and disseminated forms of TB in children [1], but fails to prevent adult pulmonary TB that represents the bulk of the global disease burden [2].. Therefore, to develop a novel vaccine or vaccination strategy to augment and prolong protection against M. tuberculosis in adult is a high priority to reduce the worldwide morbidity and mortality from TB. Article Title: Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Article Snippet: Four weeks after the third immunization, spleens were aseptically harvested from four mice ⁄ group and gently ground through a 70-lm cell strainer, and then, single-cell suspensions were prepared with Gradient Centrifugation:Article Title: Prolonged intervals during Mycobacterium tuberculosis subunit vaccine boosting contributes to eliciting immunity mediated by central memory-like T cells. Article Snippet: It is believed that central memory T cells (TCM) provide long-term protection against tuberculosis (TB).. However, the effects of TB subunit vaccine immunization schedule, especially the vaccination intervals, on T cell immune memory is still unclear.. In this study, mice were immunized with fusion protein ESAT6-Ag85B-MPT64 (190–198)-Mtb8.4-Rv2626c (LT70) based subunit vaccine three times according to the following schedules: 1 0, 3rd and 6th week respectively (0-3-6w), 2 0, 4th and 12th week (0-4-12w), and 3 0, 4th and 24th week (0-424w). Article Title: Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Article Snippet: To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4–HspX (MH for short) without affinity tag with potential advantage for clinical use.. The human T-cell responses to MH were evaluated for its immunogenicity.. Furthermore, MH was emulsified in an adjuvant composed of N,N′-dimethyl-N,N′dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. Article Title: Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Article Snippet: The current vaccine against Mycobacterium tuberculosis, Mycobacterium bovis bacillus Calmette-Guérin (BCG), has been used as the only vaccine against tuberculosis (TB) for about 90 years.. It has proven capacity to efficiently prevent severe and disseminated forms of TB in children [1], but fails to prevent adult pulmonary TB that represents the bulk of the global disease burden [2].. Therefore, to develop a novel vaccine or vaccination strategy to augment and prolong protection against M. tuberculosis in adult is a high priority to reduce the worldwide morbidity and mortality from TB. Article Title: Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Article Snippet: Four weeks after the third immunization, spleens were aseptically harvested from four mice ⁄ group and gently ground through a 70-lm cell strainer, and then, single-cell suspensions were prepared with |